Clinical TrialsThe study's updated protocol and higher volume clinical sites are expected to significantly accelerate enrollment in the coming months.
Financial PositionThe private placement with Nantahala Capital, Rosalind Advisors, and CEO Vince Angotti provides Talphera with significant funding, supporting its initiatives and potentially strengthening its financial position.
Regulatory ApprovalTalphera reached an agreement with the FDA to reduce the number of patients for the Phase 3 NEPHRO CRRT study to 70, which should allow the trial to complete faster and reduce potential total cash expenses.